Cancer is a complex human disease involving de-regulation of one or many developmental pathways. Aberrant activation of canonical Wnt signaling pathway, one of the most important developmental pathways, is a common cause of various carcinomas. Therefore, it is possible that potential cancer drugs can be developed by targeting the different nodal points of this signaling pathway. MYCN is a transcription factor of MYC family proto-onco gene. N-Myc over expression is known to be associated with various childhood tumors like neuroblastomas, medulloblastomas and prostate and lungs cancers in adults. MicroRNAs are short non-protein coding RNAs that bring about translational repression of the target gene by binding to its 3’UTR. Reports show that microRNAs play a significant role in carcinogenesis by acting as oncogenes or tumor suppressors. Oncogenic potential of hsa-miR-543 has been shown in prostate and cervical cancers, whereas, it tumor suppressive role has been reported in gliomas and colorectal cancers. Neuroblastoma patients show allelic loss of chromosome 14q, where miR-543 is located indicating the possibility of miR-543 playing an important role in neuroblastoma progression and prognosis. In the current study, we demonstrated that over-expression of miR-543 down-regulates the endogenous expression of N-Myc in HEK293FT cells. Also, it is shown to target FZD4, thereby, indirectly affecting the expression of other downstream genes of Wnt signaling including CTNNB1, TCF4 and LEF1. Therefore, our results suggest that miR-543 plays a significant role in suppressing the carcinomas resulted due to the over-expression of N-Myc and/or activation of Wnt pathway and may prove to be a potential target for novel cancer therapy.
| DOI | 10.11648/j.jctr.20180602.14 |
| Published in | Journal of Cancer Treatment and Research (Volume 6, Issue 2, June 2018) |
| Page(s) | 31-36 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
WNT Signaling Pathway, MYCN Proto-oncogene (MYCN), hsa-miR-543
| [1] | Grizz F., Internati M. C. Cancer: Looking for simplicity and finding complexity. Cancer Cell Int. 2006; 6: 1-7. |
| [2] | Polakis P. The oncogenic activation of β-catenin. Current Opinion in Genetics & Development. 1999; 9: 15-21. |
| [3] | Waltzer, L., Bienz, M. A function of CBP as a transcriptional co-activator during Dpp signalling. EMBO J. 1999; 18: 1630-1641. |
| [4] | Behrens, J. Cross-regulation of the Wnt signalling pathway: a role of MAP kinases. J. Cell Sci. 2000; 113: 911-919. |
| [5] | Liu F., Miller S. E. Wnt/β-catenin Signaling in Oral Tissue Development and Disease. J Dent Res. 2010; 89 (4): 318-330. |
| [6] | Wang Y., et al, Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res. 2009; 15 (18):5784-93. |
| [7] | Bhanot, P., Brink, M., Samos, C. H., Hseih, J. C., Wang, W., Macke, J. P., Andew, D., Nathans, J., and Nusse, R. 1996. A new member of the frizzled family from Drosophila functions as a wingless receptor. Nature 282: 225–230. |
| [8] | Yang-Snyder, J., Miller, J. R., Brown, J. D., Lai, C. J., and Moon, R. T. 1996. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr. Biol. 6: 1302–1306. |
| [9] | He, X., Saint-Jeannet, J. P., Wang, Y., Nathans, J., Dawid, I., and Varmus, H. 1997. A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 275: 1652– 1654. |
| [10] | Itoh, K., Krupnik, V. E., and Sokol, S. Y. 1998. Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin. Curr. Biol. 8: 591–594. |
| [11] | Kishida, S., Yamamoto, H., Hino, S., Ikeda, S., Kishida, M., and Kikuchi, A. 1999. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate betacatenin stability. Mol. Cell. Biol. 19: 4414–4422. |
| [12] | Lee, J. S., Ishimoto, A., and Yanagawa, S. 1999. Characterization of mouse dishevelled (Dvl) proteins in Wnt/Wingless signaling pathway. J. Biol. Chem. 274: 21464–21470. |
| [13] | Peters, J. M., McKay, R. M., McKay, J. P., and Graff, J. M. 1999. Casein kinase I transduces Wnt signals. Nature 401: 345–350. |
| [14] | Smalley, M. J., Sara, E., Paterson, H., Naylor, S., Cook, D., Jayatilake, H., Fryer, L. G., Hutchinson, L., Fry, M. J., and Dale, T. C. 1999. Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 18: 2823–2835. |
| [15] | Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., and Polakis, P. 1996. Binding of GSK3β to the APC- β -catenin complex and regulation of complex assembly. Science 272: 1023–1026. |
| [16] | Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D., and Moon, R. T. 1996. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes & Dev. 10: 1443–1454. |
| [17] | Yamamoto, H., Kishida, S., Kishida, M., Ikeda, S., Takada, S., and Kikuchi, A. 1999. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3β regulates its stability. J. Biol. Chem. 274: 10681–10684. |
| [18] | Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. 1996. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382: 638–642. |
| [19] | Molenaar, M., van de Wetering, M., Oosterwegel, M., PetersonMaduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O., and Clevers, H. 1996. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86: 391–399. |
| [20] | Hart, M., Concordet, J. P., Lassot, I., Albert, I., del los Santos, R., Durand, H., Perret, C., Rubinfeld, B., Margottin, F., Benarous, R., et al. 1999. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 9: 207–210. |
| [21] | Giles RH, Van ES, Clevers H. Caught up in a Wnt storm: Wnt signaling in Cancer. Biochem Biophys Acta. 2003; 1653 (1): 1-24. |
| [22] | Clevers H, Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res. 2006 Jan 1; 66 (1):2-5. |
| [23] | Klaus A and Birchmeier W. Wnt signaling and its impact on development and cancer. Nat Rev Cancer, 2008; 8 (5): 387-98. |
| [24] | Yang LH, Xu HT, Han Y, Li QC, Liu Y, Zhao Y, Yang ZQ, Dong QZ, Miao Y, Dai SD, Wang EH: Axin downregulates TCF-4 transcription via beta-catenin, but not p53, and inhibits the proliferation and invasion of lung cancer cells. Mol Cancer 2010, 9:25. |
| [25] | Ying Y, Tao Q: Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 2009, 4:307–312. |
| [26] | Mathsyaraja H., Eisenman R. N. Parsing Myc paralogs in oncogenesis. Cancer Cell. 2016; 29: 1–2. |
| [27] | Wilde B. R., Ayer D. E. Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis. Br. J. Cancer. 2015; 113: 1529–1533. |
| [28] | Gherardi S., Valli E., Erriquez D., Perini G. MYCN-mediated transcriptional repression in neuroblastoma: The other side of the coin. Front. Oncol. 2013; 3: 42. |
| [29] | Ribeiro D., Klarqvist M. D., Westermark U. K., Oliynyk G., Dzieran J., Kock A., Savatier Banares C., Hertwig F., Johnsen J. I., Fischer M., et al. Regulation of nuclear hormone receptors by MYCN-driven mirnas impacts neural differentiation and survival in neuroblastoma patients. Cell Rep. 2016; 16: 979–993. |
| [30] | Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science, 2001; 294 (5543): 862-4. |
| [31] | Ambros V., Bartel B., A uniform system for microRNA annotation RNA. 2003; 9 (3): 277-79. |
| [32] | Du Y., Liu X. H., Zhu H. C., Wang L., Ning J. Z., Xiao C. C. MiR-543 Promotes Proliferation and Epithelial - Mesenchymal Transition in Prostate Cancer via Targeting RKIP. Cell Physiol Biochem. 2017; 41 (3): 1135-1146. |
| [33] | Dang H., Zheng P., Liu Y. MicroRNA-543 acts as a prognostic marker and promotes the cell proliferation in cervical cancer by BRCA1-interacting protein 1. Tumor Biology. 2017; 39 (2). |
| [34] | Xu L, Yu J, Wang Z, Zhu Q, Wang W, Lan Q. miR-543 functions as a tumor suppressor in glioma in vitro and in vivo. Oncol Rep. 2017; 38 (2): 725- 734. |
| [35] | Chuannan F., Yancheng L., et al. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2 Oncotarget. 2016 Apr 19; 7 (16): 21825–21839. |
| [36] | Hoshi M., et al., Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss, Br. J. Cancer 82 (11) (2000) 1801–1807. |
| [37] | Thompson P. M., et al., Loss of heterozygosity for chromosome 14q in neuroblastoma, Med. Pediatr. Oncol. 36 (1) (2001) 28–31. |
| [38] | Roth S. A., et al. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment. Cancer Letters. 2015; 372 (1). |
APA Style
Annada Anil Joshi, Alka Vishwas Nerurkar, Neelam Vishwanath Shirsat. (2018). hsa-miR-543 Acts as a Tumor Suppressor by Targeting NMYC. Journal of Cancer Treatment and Research, 6(2), 31-36. https://doi.org/10.11648/j.jctr.20180602.14
ACS Style
Annada Anil Joshi; Alka Vishwas Nerurkar; Neelam Vishwanath Shirsat. hsa-miR-543 Acts as a Tumor Suppressor by Targeting NMYC. J. Cancer Treat. Res. 2018, 6(2), 31-36. doi: 10.11648/j.jctr.20180602.14
AMA Style
Annada Anil Joshi, Alka Vishwas Nerurkar, Neelam Vishwanath Shirsat. hsa-miR-543 Acts as a Tumor Suppressor by Targeting NMYC. J Cancer Treat Res. 2018;6(2):31-36. doi: 10.11648/j.jctr.20180602.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jctr.20180602.14,
author = {Annada Anil Joshi and Alka Vishwas Nerurkar and Neelam Vishwanath Shirsat},
title = {hsa-miR-543 Acts as a Tumor Suppressor by Targeting NMYC},
journal = {Journal of Cancer Treatment and Research},
volume = {6},
number = {2},
pages = {31-36},
doi = {10.11648/j.jctr.20180602.14},
url = {https://doi.org/10.11648/j.jctr.20180602.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20180602.14},
abstract = {Cancer is a complex human disease involving de-regulation of one or many developmental pathways. Aberrant activation of canonical Wnt signaling pathway, one of the most important developmental pathways, is a common cause of various carcinomas. Therefore, it is possible that potential cancer drugs can be developed by targeting the different nodal points of this signaling pathway. MYCN is a transcription factor of MYC family proto-onco gene. N-Myc over expression is known to be associated with various childhood tumors like neuroblastomas, medulloblastomas and prostate and lungs cancers in adults. MicroRNAs are short non-protein coding RNAs that bring about translational repression of the target gene by binding to its 3’UTR. Reports show that microRNAs play a significant role in carcinogenesis by acting as oncogenes or tumor suppressors. Oncogenic potential of hsa-miR-543 has been shown in prostate and cervical cancers, whereas, it tumor suppressive role has been reported in gliomas and colorectal cancers. Neuroblastoma patients show allelic loss of chromosome 14q, where miR-543 is located indicating the possibility of miR-543 playing an important role in neuroblastoma progression and prognosis. In the current study, we demonstrated that over-expression of miR-543 down-regulates the endogenous expression of N-Myc in HEK293FT cells. Also, it is shown to target FZD4, thereby, indirectly affecting the expression of other downstream genes of Wnt signaling including CTNNB1, TCF4 and LEF1. Therefore, our results suggest that miR-543 plays a significant role in suppressing the carcinomas resulted due to the over-expression of N-Myc and/or activation of Wnt pathway and may prove to be a potential target for novel cancer therapy.},
year = {2018}
}
TY - JOUR T1 - hsa-miR-543 Acts as a Tumor Suppressor by Targeting NMYC AU - Annada Anil Joshi AU - Alka Vishwas Nerurkar AU - Neelam Vishwanath Shirsat Y1 - 2018/08/31 PY - 2018 N1 - https://doi.org/10.11648/j.jctr.20180602.14 DO - 10.11648/j.jctr.20180602.14 T2 - Journal of Cancer Treatment and Research JF - Journal of Cancer Treatment and Research JO - Journal of Cancer Treatment and Research SP - 31 EP - 36 PB - Science Publishing Group SN - 2376-7790 UR - https://doi.org/10.11648/j.jctr.20180602.14 AB - Cancer is a complex human disease involving de-regulation of one or many developmental pathways. Aberrant activation of canonical Wnt signaling pathway, one of the most important developmental pathways, is a common cause of various carcinomas. Therefore, it is possible that potential cancer drugs can be developed by targeting the different nodal points of this signaling pathway. MYCN is a transcription factor of MYC family proto-onco gene. N-Myc over expression is known to be associated with various childhood tumors like neuroblastomas, medulloblastomas and prostate and lungs cancers in adults. MicroRNAs are short non-protein coding RNAs that bring about translational repression of the target gene by binding to its 3’UTR. Reports show that microRNAs play a significant role in carcinogenesis by acting as oncogenes or tumor suppressors. Oncogenic potential of hsa-miR-543 has been shown in prostate and cervical cancers, whereas, it tumor suppressive role has been reported in gliomas and colorectal cancers. Neuroblastoma patients show allelic loss of chromosome 14q, where miR-543 is located indicating the possibility of miR-543 playing an important role in neuroblastoma progression and prognosis. In the current study, we demonstrated that over-expression of miR-543 down-regulates the endogenous expression of N-Myc in HEK293FT cells. Also, it is shown to target FZD4, thereby, indirectly affecting the expression of other downstream genes of Wnt signaling including CTNNB1, TCF4 and LEF1. Therefore, our results suggest that miR-543 plays a significant role in suppressing the carcinomas resulted due to the over-expression of N-Myc and/or activation of Wnt pathway and may prove to be a potential target for novel cancer therapy. VL - 6 IS - 2 ER -
Information
Email: